Division of Compensation Analysis and

Support

Program Evaluation Report

Document Number: DCAS-PER-080

Effective Date: 8/30/2017

Revision No. 0

General Steel Industries Page 1 of 2

Author: Signature on file Date: 8/30/2017 Dave Allen, HP Team Leader

Approval: Signature on file Date: 8/30/2017 

 J. W. Neton, Associate Director for Science

Supersedes: none

RECORD OF ISSUE/REVISIONS

ISSUE 

AUTHORIZATION 

DATE

EFFECTIVE

DATE

REV. NO. DESCRIPTION

8/30/2017 8/30/2017 0 New document to determine the effect of 

revision 2 and 3 to Battelle-TBD-6000 

Appendix BB (General Steel Industries)

on previously completed claims.

1.0 Description

Revision 1 of Battelle-6000 Appendix BB (Appendix BB) was issued on 6/6/2014. A 

Program Evaluation Report (DCAS-PER-0057) was issued on 3/11/2015 evaluating the 

effect of this revision. Revision 2 of Appendix BB was issued on 5/26/2016 and revision 

3 on 2/9/2017. The changes made in revision 2 and revision 3 are the subject of this 

PER.

2.0 Issue Evaluation

For the residual contamination period at GSI (7/1/1966 through 12/31/1993) the 

prescriptive external dose and inhalation intakes were identical in revisions 1, 2 and 3. 

The ingestion intake decreased from revision 1 to revision 2 and remained the same in 

revision 3.

During the operational period (10/1/1952 through 6/30/1966) inhalation intakes remained 

the same, except that inhalation intakes increased in revision 2 during the 1966 

operational period (1/1/1966 through 6/30/1966). The inhalation intakes remained the 

same in revision 3. Ingestion intakes decreased from revision 1 to revision 2 and 

remained the same in revision 3. 
Division of Compensation Analysis and 

Support

Program Evaluation Report

Document Number: DCAS-PER-080 

Effective Date: 8/30/2017 Revision No.: 0 Page 2 of 2

External dose for radiographers during the operational period is described in table 8 and 

table 9 of Appendix BB for each of the revisions. The tables provide the gamma, neutron 

and beta doses for most organs (Table 8) and for the skin of the hands and forearms 

(Table 9). While some of the prescribed doses decreased, at least one of the prescribed 

doses increased in each year after revision 1. 

The overall effect is that at least one aspect of the dose estimate increased each year 

during the operational period. None of the prescribed doses or intakes increased during 

the residual period. Therefore, all previously completed claims with employment during 

the operational period will be reevaluated under this Program Evaluation Report (PER). 

3.0 Plan for Resolving Corrective Action 

All GSI claims completed prior to 2/9/2017, with a probability of causation (POC) less 

than 50%, and employment at GSI during the operational period were included in the 

selected population of claims for this PER. This resulted in a total of 71 claims that 

required further evaluation. The dose for each of the 71 cases was recalculated using the 

methodology described in revision 3 of Appendix BB, as well as the current revision of 

any other applicable documents. Fifty-five of these reworked claims had a POC below 

45% while 4 had a POC above 52%. For the remaining 12 claims with POC’s greater 

than 45% but less than 52%, IREP was run 30 times at 10,000 iterations per NIOSH 

procedures. The resulting POC was greater than 50% for 2 claims and less than 50% for 

the other 10 claims. 

NIOSH will provide the Department of Labor with the list of all the claims evaluated 

under this PER. Further, NIOSH will request the return of the 6 claims that would now 

result in a probability of causation greater than 50%.